v3.26.1
Collaboration and License Agreements - ModernaTX, Inc - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jan. 31, 2023
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Deferred revenue   $ 28,467 $ 94,063 $ 212,315
ModernaTX, Inc        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Deferred revenue   9,300    
ModernaTX, Inc | Collaboration and License Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Upfront payment received $ 35,000      
Upfront consideration, pre-paid research and development service fees 5,000      
Total transaction price   51,700    
Upfront Fee Received   30,000    
Estimated research fund   21,700    
Deferred revenue   9,300 9,300  
Amount due from agreement   $ 0 $ 900  
Estimated research service period   4 years    
ModernaTX, Inc | Collaboration and License Agreement | Maximum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Contingent milestone payments receivable $ 1,200,000